Maplight Therapeutics

1 trends tracked about this subject — the full history, oldest to newest below.

▲ Peaking Business

MapLight Therapeutics shares have declined following the release of mixed Phase 2 trial results for its schizophrenia drug candidate.

7 sources 7 articles v 5 28m ago